Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Susan K. Hoiseth is active.

Publication


Featured researches published by Susan K. Hoiseth.


The Journal of Infectious Diseases | 2009

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis

Ellen Murphy; Lubomira Andrew; Kwok-Leung Lee; Deborah A. Dilts; Lorna Nunez; Pamela S. Fink; Karita Ambrose; Ray Borrow; Jamie Findlow; Muhamed-Kheir Taha; Ala-Eddine Deghmane; Paula Kriz; Martin Musilek; Jitka Kalmusova; Dominique A. Caugant; Torill Alvestad; Leonard W. Mayer; Claudio T. Sacchi; Xin Wang; Diana Martin; Anne von Gottberg; Mignon du Plessis; Keith P. Klugman; Annaliesa S. Anderson; Kathrin U. Jansen; Gary W. Zlotnick; Susan K. Hoiseth

BACKGROUND Recombinant forms of Neisseria meningitidis human factor H binding protein (fHBP) are undergoing clinical trials in candidate vaccines against invasive meningococcal serogroup B disease. We report an extensive survey and phylogenetic analysis of the diversity of fhbp genes and predicted protein sequences in invasive clinical isolates obtained in the period 2000-2006. METHODS Nucleotide sequences of fhbp genes were obtained from 1837 invasive N. meningitidis serogroup B (MnB) strains from the United States, Europe, New Zealand, and South Africa. Multilocus sequence typing (MLST) analysis was performed on a subset of the strains. RESULTS Every strain contained the fhbp gene. All sequences fell into 1 of 2 subfamilies (A or B), with 60%-75% amino acid identity between subfamilies and at least 83% identity within each subfamily. One fHBP sequence may have arisen via inter-subfamily recombination. Subfamily B sequences were found in 70% of the isolates, and subfamily A sequences were found in 30%. Multiple fHBP variants were detected in each of the common MLST clonal complexes. All major MLST complexes include strains in both subfamily A and subfamily B. CONCLUSIONS The diversity of strains observed underscores the importance of studying the distribution of the vaccine antigen itself rather than relying on common epidemiological surrogates such as MLST.


Vaccine | 2010

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

Han-Qing Jiang; Susan K. Hoiseth; Shannon L. Harris; Lisa K. McNeil; Duzhang Zhu; Cuiwen Tan; Adrienne A. Scott; Kristin Alexander; Kathryn Mason; Lynn Miller; Ida DaSilva; Michelle Mack; Xiao-Juan Zhao; Michael W. Pride; Lubomira Andrew; Ellen Murphy; Michael Hagen; Roger French; Ashoni Arora; Thomas R. Jones; Kathrin U. Jansen; Gary W. Zlotnick; Annaliesa S. Anderson

Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and vaccine potential of mono- or bivalent fHBP-containing vaccines. A bivalent fHBP vaccine composed of a member of each subfamily elicited substantially broader bactericidal activity against MnB strains expressing heterologous fHBP than did either of the monovalent vaccines. Bivalent rabbit immune sera tested in serum bactericidal antibody assays (SBAs) against a diverse panel of MnB clinical isolates killed 87 of the 100 isolates. Bivalent human immune sera killed 36 of 45 MnB isolates tested in SBAs. Factors such as fHBP protein variant, PorA subtype, or MLST were not predictive of whether the MnB strain could be killed by rabbit or human immune sera. Instead, the best predictor for killing in the SBA was the level of in vitro surface expression of fHBP. The bivalent fHBP vaccine candidate induced immune sera that killed MnB isolates representing the major MLST complexes, prevalent PorA subtypes, and fHBP variants that span the breadth of the fHBP phylogenetic tree. Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed.


Journal of Biological Chemistry | 2009

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

Alessandro Mascioni; Breagh E. Bentley; Rosaria Camarda; Deborah A. Dilts; Pamela S. Fink; Viktoria Gusarova; Susan K. Hoiseth; Jaison Jacob; Shuo L. Lin; Karl Malakian; Lisa K. McNeil; Terri Mininni; Franklin J. Moy; Ellen Murphy; Elena Novikova; Scott Sigethy; Yingxia Wen; Gary W. Zlotnick; Désirée H. H. Tsao

LP2086 is a family of outer membrane lipoproteins from Neisseria meningitidis, which elicits bactericidal antibodies and are currently undergoing human clinical trials in a bivalent formulation where each antigen represents one of the two known LP2086 subfamilies. Here we report the NMR structure of the recombinant LP2086 variant B01, a representative of the LP2086 subfamily B. The structure reveals a novel fold composed of two domains: a “taco-shaped” N-terminal β-sheet and a C-terminal β-barrel connected by a linker. The structure in micellar solution is consistent with a model of LP2086 anchored to the outer membrane bilayer through its lipidated N terminus. A long flexible chain connects the folded part of the protein to the lipid anchor and acts as spacer, making both domains accessible to the host immune system. Antibodies broadly reactive against members from both subfamilies have been mapped to the N terminus. A surface of subfamily-defining residues was identified on one face of the protein, offering an explanation for the induction of subfamily-specific bactericidal antibodies.


Vaccine | 2011

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

Xin Wang; Amanda C. Cohn; Maurizio Comanducci; Lubomira Andrew; Xin Zhao; Jessica R. MacNeil; Susanna Schmink; Alessandro Muzzi; Stefania Bambini; Rino Rappuoli; Mariagrazia Pizza; Ellen Murphy; Susan K. Hoiseth; Kathrin U. Jansen; Annaliesa S. Anderson; Lee H. Harrison; Thomas A. Clark; Nancy E. Messonnier; Leonard W. Mayer

Neisseria meningitidis (Nm) serogroups B, C and Y are the major causes of meningococcal diseases in the United States. NmB accounts for ∼1/3 of the disease but no licensed vaccine is yet available. Two candidate vaccines are being developed specifically to target NmB, but may also provide protection against other serogroups. To assess the potential impact of these vaccines on NmB and other serogroups causing disease in the US, we determined the prevalence, genetic diversity and epidemiological characteristics of three candidate antigen genes in Nm isolates collected through Active Bacterial Core surveillance (ABCs), a population-based active surveillance program. fHbp was detected in all NmB, NmY and NmW135 isolates. Eleven NmC isolates contain fHbp with a single base-pair deletion creating a frame shift in the C-terminal region. Among NmB, 59% were FHbp subfamily/variant B/v1 and 41% A/v2-3. Among NmC and NmY, 39% and 3% were B/v1, respectively. nadA was detected in 39% of NmB, 61% of NmC and 4% of NmY. Among isolates tested, nhbA was present in all NmB and 96% of non-B. For the subset of strains sequenced for NadA and NhbA, pairwise identity was greater than 93% and 78%, respectively. The proportion of FHbp subfamily/variant was different between ABCs site and year, but no linear temporal trend was observed. Although assessment of the vaccine coverage also requires understanding of the antigen expression and the ability to induce bactericidal activity, our finding that all isolates contain one or more antigen genes suggests these candidate vaccines may protect against multiple Nm serogroups.


Vaccine | 2009

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide

Lisa K. McNeil; Ellen Murphy; Xiao-Juan Zhao; Stephen Guttmann; Shannon L. Harris; Adrienne A. Scott; Cuiwen Tan; Michelle Mack; Ida DaSilva; Kristin Alexander; Kathryn Mason; Han-Qing Jiang; Duzhang Zhu; Terri Mininni; Gary W. Zlotnick; Susan K. Hoiseth; Thomas R. Jones; Michael W. Pride; Kathrin U. Jansen; Annaliesa S. Anderson

The outer membrane protein LP2086, a human factor H binding protein, is undergoing clinical trials as a vaccine against invasive serogroup B meningococcal (MnB) disease. As LP2086 is a surface protein, expression of capsular polysaccharide could potentially limit accessibility of anti-LP2086 antibodies to LP2086 expressed on the surface of bacteria. To determine whether variability in expression levels of the serogroup B capsule (Cap B) might interfere with accessibility of anti-LP2086 antibody binding to LP2086, we evaluated the ability of anti-Cap B and anti-LP2086 antibodies to bind to the surface of 1263 invasive clinical MnB strains by flow cytometry. One of the anti-LP2086 monoclonal antibodies used recognizes virtually all LP2086 sequence variants. Our results show no correlation between the amount of Cap B expressed and the binding of anti-LP2086 antibodies. Furthermore, the susceptibility of MnB bacteria to lysis by anti-LP2086 immune sera was independent of the level of Cap B expressed. The data presented in this paper demonstrates that Cap B does not interfere with the binding of antibodies to LP2086 expressed on the outer membrane of MnB clinical isolates.


Microbiology and Molecular Biology Reviews | 2013

Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

Lisa K. McNeil; Robert John Zagursky; Shuo L. Lin; Ellen Murphy; Gary W. Zlotnick; Susan K. Hoiseth; Kathrin U. Jansen; Annaliesa S. Anderson

SUMMARY Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans and can cause devastating invasive disease. Although capsular polysaccharide-based vaccines against serogroups A, C, Y, and W135 are widely available, the pathway to a broadly protective vaccine against serogroup B has been more complex. The last 11 years has seen the discovery and development of the N. meningitidis serogroup B (MnB) outer membrane protein factor H binding protein (fHBP) as a vaccine component. Since the initial discovery of fHBP, a tremendous amount of work has accumulated on the diversity, structure, and regulation of this important protein. fHBP has proved to be a virulence factor for N. meningitidis and a target for functional bactericidal antibodies. fHBP is critical for survival of meningococci in the human host, as it is responsible for the primary interaction with human factor H (fH). Binding of hfH by the meningococcus serves to downregulate the host alternative complement pathway and helps the organism evade host innate immunity. Preclinical studies have shown that an fHBP-based vaccine can elicit serum bactericidal antibodies capable of killing MnB, and the vaccine has shown very encouraging results in human clinical trials. This report reviews our current knowledge of fHBP. In particular, we discuss the recent advances in our understanding of fHBP, its importance to N. meningitidis, and its potential role as a vaccine for preventing MnB disease.


Human Vaccines | 2011

Challenges for the evaluation of Staphylococcus aureus protein based vaccines: Monitoring antigenic diversity

Ellen Murphy; Shuo L. Lin; Lorna Nunez; Lubomira Andrew; Pamela S. Fink; Deborah A. Dilts; Susan K. Hoiseth; Kathrin U. Jansen; Annaliesa S. Anderson

Clumping factors A (ClfA) and B (ClfB) are Staphylococcus aureus virulence proteins that are displayed on the cell surface of the organism and have potential as vaccine antigens for the prevention of S. aureus disease. Here we evaluate the phylogeny of S. aureus in the context of antigenic variation of these two surface proteins. ClfA and ClfB gene sequences, along with epidemiological markers (MLST, spa and capsule genotype) were obtained for 224 S. aureus isolates including both historical strains and a collection representative of current MRSA isolates from the United States. Variation within ClfA and ClfB was consistent with the established population biology of S. aureus, namely, that S. aureus strains belong to a relatively small number of clonal lineages, with evolution proceeding mainly by mutation and with little to no recombination between clades. Thus most variation in ClfA and ClfB occurs between but not within lineages, and particular groups of ClfA and ClfB variants are closely linked. This has important implications for vaccine development and assessment as it suggests that a relatively small survey of strains will be representative of the total population variation, whereas for species that evolve mainly by recombination, such as Neisseria meningitidis, analysis of a much larger number of strains is needed to accomplish the same purpose. Our study also revealed evidence for the de-evolution of ClfB and therefore its reduced suitability as a target for vaccine development compared to ClfA.


Pediatric Infectious Disease Journal | 2013

A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.

Susan K. Hoiseth; Ellen Murphy; Lubomira Andrew; Ulrich Vogel; Matthias Frosch; Wiebke Hellenbrand; Raquel Abad; Julio A. Vázquez; Ray Borrow; Jamie Findlow; Muhamed-Kheir Taha; Ala-Eddine Deghmane; Dominique A. Caugant; Paula Kriz; Martin Musilek; Leonard W. Mayer; Xin Wang; Jessica R. MacNeil; Laura J. York; Charles Y. Tan; Kathrin U. Jansen; Annaliesa S. Anderson

Background: Recombinant vaccines containing factor H–binding protein (fHBP) have been developed for the purpose of protection from invasive meningococcal serogroup B disease. Neisseria meningitidis fHBP sequences can be divided into 2 genetically and immunologically distinct subfamilies (A and B); thus, cross protection is conferred within but not between subfamilies. A comprehensive understanding of fHBP epidemiology is required to accurately assess the potential vaccine impact when considering different vaccination implementation strategies. Methods: Systematically collected invasive meningococcal serogroup B isolates from England, Wales, Northern Ireland, the United States, Norway, France and the Czech Republic were previously characterized for fHBP sequence. This study expanded the evaluation with additional meningococcal serogroup B disease isolates from Spain (n = 346) and Germany (n = 205). This expanded set (n = 1841), collected over a 6-year period (2001 to 2006), was evaluated for fHBP sequence and fHBP subfamily relative to patient age. Results: All 1841 isolates contained fhbp. fHBP sequences from Spain and Germany fell within the previously described subfamilies, with 69% of isolates belonging to subfamily B and 31% to subfamily A; prevalent sequence variants were also similar. Stratification of data by age indicated that disease in infants <1 year of age was caused by a significantly higher proportion of isolates with fHBP subfamily A variants than that seen in adolescents and young adults 11–25 years (47.7% versus 19.5%, P < 0.0001, respectively). Conclusions: These observations highlight a difference in epidemiology of fHBP subfamilies in different age groups, with fHBP subfamily A strains causing more disease in vulnerable populations, such as infants, than in adolescents.


Vaccine | 2010

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

Dlawer A. A. Ala'Aldeen; Mike Flint; Neil J. Oldfield; Sherko A. Omer; Lisa K. McNeil; Qin Jiang; Ellen Murphy; Peter C. Giardina; Elena Novikova; Ingrid L. Dodge-Scully; Christopher D. Bayliss; David P. J. Turner; Keith R. Neal; Susan K. Hoiseth; Kathrin U. Jansen; Annaliesa S. Anderson

Recombinant forms of Neisseria meningitidis factor H binding protein (fHBP) are undergoing clinical trials in candidate vaccines against serogroup B meningococcal disease. Little is known, however, about the host response to fHBP during natural carriage and disease. Here we report a longitudinal study of the antibody response to fHBP in healthy meningococcal carriers and non-carriers, and in patients with invasive meningococcal disease. Using a highly sensitive quantitative immunoassay, anti-fHBP antibodies were detected in sera from all healthy carriers and non-carriers. Carriers had significantly higher anti-fHBP antibody concentrations than non-carriers. Antibody responses similar to those seen in non-carrier subjects were detected in the sera of patients with invasive disease upon their admission to the hospital. The serum anti-fHBP antibody concentrations in these patients generally rose to reach levels similar to those seen in carriers. No correlation between levels of surface fHBP expressed in vitro by the infecting N. meningitidis strain and the magnitude of antibody responses was observed. These data suggest that fHBP is expressed in vivo during both carriage and invasive disease at levels high enough to elicit a robust antibody response.


Vaccine | 2011

Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa.

Kedibone M. Mothibeli; Mignon du Plessis; Anne von Gottberg; Ellen Murphy; Susan K. Hoiseth; Gary W. Zlotnick; Keith P. Klugman

Factor H binding protein (fHBP) is currently under investigation as a potential vaccine antigen for protection against meningococcal serogroup B (MenB) disease. This study describes the distribution of genotypes among all (n=58) MenB, and a total of 80 representative non-MenB (serogroups A, C, Y and W135) isolates causing invasive disease in South Africa in 2005 using fHBP sequence analysis, PorA, FetA and multilocus sequence typing. There was less fHBP diversity among non-MenB isolates compared to MenB isolates. fHBP subfamily variant A32 was the most common fHBP variant among MenB isolates and was represented by 17% (10/58) of the isolates, while fHBP variant B16 was the most prevalent variant among non-MenB strains and was represented by 40% (32/80) of isolates. Overall, subfamily B domain N6 (modular group I) was most prevalent (57%, 79/138). Twenty PorA and 16 FetA types were identified among MenB isolates whereas non-MenB serogroups were largely associated with specific serosubtypes. The most common MenB clonal complex (ST-41/44/lineage 3) was represented by 29% (17/58) of the MenB isolates, while each of the non-MenB serogroups had a major clone represented by at least 75% of the isolates within the serorogroup. Our data highlight that non-MenB meningococcal isolates also harbor fHBP.

Collaboration


Dive into the Susan K. Hoiseth's collaboration.

Researchain Logo
Decentralizing Knowledge